Depression and Cannabis: How CBD Can Support Treatment and Why It Shouldn't Replace It

Depression is one of the most common causes of disability worldwide, affecting approximately 280 million people globally ("Depressive Disorder Fact Sheet", WHO, 2023). In Poland, according to the EZOP II study, about 3.9% of adults struggle with depressive disorders in their lifetime, and with all mood disorders combined, about 4.7% ("EZOP II Study", Institute of Psychiatry and Neurology, 2021). Cannabis, particularly cannabidiol (CBD), is gaining increasing interest as a potential support for pharmacotherapy, mainly because about 30-50% of patients with depression do not respond to the first line of SSRIs or SNRIs. In this article, we will analyze what preclinical and clinical data from 2019-2025 say, what the endocannabinoid-serotonin axis is in the context of mood, what risks are associated with THC and interactions with antidepressants, and why depression should never be treated solely with CBD oil.

/category/mental-disorders/

What is clinical depression and how does it differ from a low mood?

Clinical depression is a mood disorder characterized by a persistent drop in mood lasting at least 14 days, anhedonia, and vegetative symptoms that significantly impair functioning. According to the latest WHO estimates, global lifetime prevalence reaches 280 million people, and the annual mortality from suicides related to depression exceeds 700,000 cases ("Suicide Data", WHO, 2023). This is not just a temporary bad week; it is a brain disease that requires treatment.

Depressive episode, recurrent depression, and dysthymia

The ICD-11 classification, which replaced ICD-10 in 2022, distinguishes between a single depressive episode, recurrent depressive disorder, and dysthymic disorder (persistent low mood lasting at least two years). A depressive episode is classified based on severity: mild, moderate, and severe (with or without psychotic symptoms). This severity determines the urgency and form of treatment.

DSM-5 and ICD-11 criteria

DSM-5 requires the presence of at least five out of nine symptoms for at least 14 days, with at least one of them involving a low mood or anhedonia (American Psychiatric Association, DSM-5-TR, 2022). Among the other symptoms are sleep disturbances, changes in appetite and weight, psychomotor retardation or agitation, fatigue, feelings of worthlessness, difficulty concentrating, and thoughts of death or suicide.

When sadness becomes depression

The reaction of sadness to loss, grief, or disappointment is a normal phenomenon and does not meet the criteria for depression. It is differentiated by duration, depth, loss of functioning, and the presence of somatic symptoms. If low mood, anhedonia, and fatigue persist for more than two weeks and worsen work, relationships, or self-care, it is a signal to contact a psychiatrist, not to use CBD oil.

Citation capsule: Clinical depression requires at least five out of nine DSM-5 symptoms for a minimum of 14 days, affects 280 million people globally, and accounts for over 700,000 suicides annually, making it one of the leading causes of years of life lost due to disability (WHO, 2023).

/terapie-z-uzyciem-psychodelikow-leczenie-zaburzen-psychicznych-mdma-i-psylocybina/

What does the epidemiology of depression look like in Poland and who is most at risk?

In Poland, according to a representative EZOP II study conducted between 2018-2021, about 3.9% of adults struggled with a depressive disorder in their lifetime, and with any mood disorder combined, 4.7% ("EZOP II Study", Institute of Psychiatry and Neurology, 2021). The number of prescriptions for antidepressants issued in Poland exceeded 17 million annually, highlighting the scale of the problem.

Gender and age differences

Women suffer from depression about twice as often as men, which results from a combination of hormonal factors (menstrual cycles, perinatal period, menopause), social factors, and inequalities in caregiving work. The highest incidence is observed in the age groups of 18-29 and 45-59 years. In men, depression more often manifests as irritability, isolation, and substance abuse, which delays diagnosis.

Depression in adolescents and seniors

According to an NFZ report, the percentage of young Poles aged 13-18 receiving psychiatric treatment increased by over 50% after the pandemic ("NFZ Report on the Mental Health of Children and Adolescents", National Health Fund, 2022). In older adults, depression may be masked by somatic complaints (pain, insomnia) and layered on chronic diseases, complicating diagnosis.

Risk factors in the Polish context

Recognized risk factors include: family burden (30-40% heritability), chronic stress, early childhood trauma, unemployment, unstable housing conditions, somatic diseases (diabetes, thyroid diseases, oncology, multiple sclerosis), alcohol abuse, and other addictions. The Polish specificity includes long waiting times for psychiatric appointments within the NFZ (averaging 3-6 months), which encourages self-treatment and seeking shortcuts.

Citation capsule: In Poland, depressive disorders affect about 3.9% of adults in their lifetime, and mood disorders a total of 4.7%, with over 17 million prescriptions for antidepressants issued annually, placing depression among the most common mental disorders (EZOP II, Institute of Psychiatry and Neurology, 2021).

How is depression diagnosed and why can't it be done independently?

Diagnosing depression requires a psychiatric examination, and online screening tools serve only as a warning signal. Typically, a doctor uses structured clinical interviews (SCID, MINI) and scales: PHQ-9, Beck Depression Inventory, Hamilton Depression Rating Scale, Montgomery-Asberg. Meta-analyses show that PHQ-9 has a sensitivity of 88% and specificity of 85% for moderate and severe depression (Levis et al., BMJ, 2019).

The role of the psychiatrist and the family doctor

In Poland, a referral is not required to see a psychiatrist, but a family doctor can initiate treatment for mild to moderate depression if they have training. In severe depression, with psychotic symptoms, suicidal thoughts, or in individuals under 18 years of age, management must be conducted by a psychiatrist. The psychiatrist assesses suicide risk, selects medication, and determines indications for hospitalization.

Excluding somatic causes

Before a doctor diagnoses depression, they should rule out somatic causes of symptoms. Common causes include: hypothyroidism (TSH, fT4), vitamin D and B12 deficiency, anemia, obstructive sleep apnea syndrome, Parkinson's disease, strokes, and drug reactions (beta-blockers, corticosteroids, interferon). A standard laboratory panel includes a complete blood count, TSH, electrolytes, glucose, liver and kidney function tests.

Why online tools are not enough

Self-filling out the PHQ-9 online and discontinuing medications based on the result is one of the most dangerous forms of self-treatment in psychiatry. Clinical scales are monitoring tools, not diagnostic ones. Without a medical examination, conditions such as bipolar disorder (where SSRIs alone can trigger mania), personality disorders, post-traumatic stress disorder, and "masked" depression through somatization will be overlooked.

Citation capsule: The PHQ-9 scale has a sensitivity of 88% and specificity of 85% in diagnosing moderate and severe depression, but it cannot replace a psychiatric examination, and self-discontinuation of medications based on an online result poses a real health risk (Levis et al., BMJ, 2019).

/glodzenie-sie-brak-apetytu-objadanie-sie-czy-cbd-moze-pomoc-w-leczeniu-zaburzen-odzywiania/

How does the endocannabinoid system work in mood regulation?

The endocannabinoid system (ECS) is a neuromodulatory network that includes CB1 and CB2 receptors, endogenous ligands (anandamide, 2-AG), and synthesis and degradation enzymes (FAAH, MAGL). Studies from 2010-2024 have shown that the ECS regulates the hypothalamic-pituitary-adrenal (HPA) axis, neurogenesis in the hippocampus, and the release of serotonin, dopamine, and norepinephrine (Hill and Patel, Neuropsychopharmacology, 2020). These three axes are precisely those that fail in depression.

CB1 receptors in the hippocampus and prefrontal cortex

CB1 receptors are most densely distributed in the hippocampus, prefrontal cortex, amygdala, and basal ganglia. They control the release of glutamate and GABA, which translates into the regulation of emotional network excitability. Changes in CB1 expression and reduced levels of anandamide have been noted in patients with depression, suggesting a state of "endocannabinoid deficiency" in some patients.

HPA axis, cortisol, and chronic stress

Chronic stress activates the HPA axis, raises cortisol, and causes atrophy of the hippocampus, a structure critical for memory and mood regulation. Endocannabinoids act as a brake on the HPA axis, suppressing the stress response. Disruption of endocannabinoid signaling is observed in both animal models of stress-induced depression and in post-mortem studies of the brains of individuals who died by suicide.

Serotonin pathway and 5-HT1A receptor

CBD acts as a partial agonist of the serotonin receptor 5-HT1A, which is a key target of buspirone and partially of SSRIs (Russo et al., Neurochemical Research, 2005). Activation of 5-HT1A in the raphe nuclei reduces the excitability of serotonergic neurons, and postsynaptic 5-HT1A in the hippocampus and prefrontal cortex mediates the antidepressant effect. This is one of the strongest mechanisms explaining CBD's potential in mood.

Neurogenesis in the hippocampus

Classical antidepressants (SSRIs, SNRIs, TCAs) require 2-6 weeks to take effect, as they stimulate neurogenesis in the dentate gyrus of the hippocampus. Preclinically, CBD also enhances neurogenesis through CB1, 5-HT1A, and the BDNF-TrkB pathway. This explains why in behavioral tests in rodents, CBD acts similarly to imipramine, but at doses that would correspond to 300-600 mg daily in humans.

Citation capsule: CBD is a partial agonist of the 5-HT1A receptor and indirectly modulates the HPA axis and neurogenesis in the hippocampus, providing a biological rationale for its antidepressant potential, although data in humans remain limited (Hill and Patel, Neuropsychopharmacology, 2020).

/endocannabinoids-relieving-stress-similarly-to-cbd-and-thc/

What do preclinical studies say about CBD as an antidepressant?

Studies on animal models are the richest source of data on the antidepressant effects of CBD. In a 2019 review, Silote and colleagues summarized over 15 preclinical studies, indicating a consistent effect of CBD in the forced swim test (FST) and tail suspension test (TST), with a mechanism dependent on 5-HT1A, BDNF, and mTOR (Silote et al., Journal of Psychiatric Research, 2019). This is the basis of the hypothesis that CBD may act "faster" than classic SSRIs.

Forced swim test and tail suspension test

FST and TST are classic paradigms used to screen antidepressants in rodents. A reduction in immobility time is interpreted as an antidepressant effect. CBD at doses of 10-30 mg/kg consistently reduces immobility, and the effect is blocked by the 5-HT1A antagonist (WAY-100635), providing evidence for a serotonergic mechanism. The effect appears after a single dose and does not require multi-week dosing.

Rapid effect similar to ketamine

The combination of CBD with ketamine, which has revolutionized the treatment of treatment-resistant depression, is interesting not only from a marketing perspective. Both substances produce a rapid antidepressant effect in rodent models, both modulate the BDNF-mTOR pathway, and both work even after a single dose. The key difference: ketamine acts through the NMDA receptor and has documented efficacy in humans, while CBD has only isolated observations in humans and no registered antidepressant indication.

Chronic unpredictable stress model (CUMS)

CUMS is a model for inducing depression in rodents through 4-6 weeks of exposure to variable stressors. In several studies, CBD at doses of 10-30 mg/kg daily reversed behavioral symptoms (anhedonia in the sucrose preference test), normalized corticosterone levels, and restored neurogenesis in the hippocampus. Mechanistically, the effect depended on CB1, 5-HT1A, and the mTOR pathway.

Limitations of animal studies

Rodent models test components of depression (anhedonia, helplessness) but not the entire clinical syndrome in humans (suicidal thoughts, feelings of guilt, social anhedonia). Doses in mg/kg used in animals, when allometrically converted to humans, yield 300-600 mg of CBD daily, which is significantly above typical supplemental doses. This is an additional consideration when extrapolating.

Citation capsule: In preclinical studies, CBD at doses of 10-30 mg/kg consistently reduces immobility in FST and TST tests in rodents, with a mechanism dependent on the 5-HT1A receptor and the BDNF-mTOR pathway, suggesting potential similar to rapid antidepressants (Silote et al., Journal of Psychiatric Research, 2019).

/cbd-czy-pomaga-w-leczeniu-depresji/

What do clinical studies of CBD in depression in humans look like?

Despite promising preclinical data, the quality of clinical evidence remains significantly weaker. A review by Crippa in 2018 summarizes: there is a lack of randomized controlled trials (RCTs) with CBD in monotherapy for depression, and available data mainly come from observational studies and populations of patients treated with medical cannabis for other indications (Crippa et al., Frontiers in Immunology, 2018). This situation persists in reviews from 2023-2025.

Observational and cohort studies

Stith and colleagues analyzed data from the Releaf app, which included thousands of cannabis doses in patients with depression. The authors reported an average reduction in depressive symptoms of about 3.76 points on a scale of 0-10 after a single dose, with better effects at higher CBD and lower THC (Stith et al., Frontiers in Psychiatry, 2020). However, this measures the acute impact on mood, not evidence of long-term remission of clinical depression.

The only uncontrolled pilot studies

Among the few prospective studies, the work of Berrendero from 2022 and open studies in patients with treatment-resistant depression are most often cited. In these case series, CBD at doses of 150-600 mg daily for 8-12 weeks resulted in a 20-35% reduction in HAM-D scores, but without a placebo group, in small trials, and with a risk of confirmation bias. In clinical practice in Polish psychiatric offices, CBD is rarely recommended as monotherapy, most often as an adjunct to support sleep or reduce co-occurring anxiety.

The gap between preclinical and clinical

The gap between strong signals in animal studies and the almost complete lack of clinical evidence has several causes: the costs of RCT in depression reach millions of euros, regulations regarding cannabis hinder academic research, and the CBD industry as a supplement has no incentives to register as a drug. This does not mean that CBD "does not work", but it means that claims of antidepressant efficacy in humans are currently speculation based on theory, not evidence.

What trials are planned for 2024-2026

The ClinicalTrials.gov database in 2025 lists several registered studies on CBD in mood disorders, mainly phase II, with doses of 300-800 mg per day and treatment periods of 6-12 weeks ("ClinicalTrials Registry", NIH, 2025). Results will be published gradually in 2026-2028. Only then will a meta-analysis with reliable effect estimates be possible.

Citation capsule: Current clinical data on CBD in depression mainly come from observational studies (Stith 2020) and small open pilot studies, without randomized controlled trials, making claims about the antidepressant efficacy of CBD a hypothesis, not evidence (Crippa et al., Frontiers in Immunology, 2018).

How does THC affect depression and why can it be dangerous?

Unlike CBD, tetrahydrocannabinol (THC) has documented biphasic effects on mood and anxiety. A meta-analysis by Gorfinkel in 2024 found that regular use of THC-rich cannabis increases the risk of depression by 37% and suicidal thoughts by 46% in young adults (Gorfinkel et al., JAMA Network Open, 2024). This is a fundamental warning for those considering "self-medication" with marijuana.

Biphasic effect of THC

At low doses (below 5-7.5 mg THC), euphoria, relaxation, and a short-term reduction in anxiety are observed. At higher doses (above 10-15 mg), dysphoria, anxiety, panic attacks, and sometimes psychotic symptoms dominate. The mechanism of this phenomenon is related to different activation of CB1 receptors in the prefrontal cortex and amygdala depending on concentration.

Risk in adolescents and young adults

The adolescent brain develops until about the age of 25, and the endocannabinoid system plays a role in regulating the maturation of synaptic connections. Exposure to high THC during this period is associated with a lasting increase in the risk of depression, psychosis, and cognitive disorders. Data from the UK and the USA show a dose-response relationship with daily use of high-THC cannabis.

Withdrawal depression

Chronic use of THC leads to down-regulation of CB1 receptors and decreased sensitivity of the endocannabinoid system. Upon withdrawal, withdrawal syndrome is observed, including insomnia, irritability, decreased appetite, and low mood lasting 2-4 weeks. During this phase, the risk of relapse into depression and suicidal thoughts increases.

When THC can help

In individual cases, under the supervision of a treating physician, low doses of THC (medical flowers with low concentration, 2-5% THC, vaporized) may be used in depression with accompanying chronic pain or post-traumatic stress disorder. However, this requires a prescription, monitoring of psychiatric symptoms, and excludes patients with a history of psychosis, bipolar disorder, or family predisposition.

Citation capsule: Regular use of high-THC cannabis increases the risk of depression by 37% and suicidal thoughts by 46% in young adults, and the biphasic effect of THC means that higher doses exacerbate depressive symptoms (Gorfinkel et al., JAMA Network Open, 2024).

/konopie-i-antydepresanty-czy-mozna-laczyc-leki-przeciwdepresyjne-z-cbd-i-marihuana/

What are the standard methods for treating depression that must be the first line?

First-line treatment for moderate to severe depression is based on a combination of pharmacotherapy and psychotherapy. A meta-analysis by Cipriani involving 21 antidepressants and over 116,000 patients showed that all studied medications are more effective than placebo, with NNT (number needed to treat) ranging from 5 to 11 (Cipriani et al., The Lancet, 2018). This means that 1 in 5-11 treated individuals experiences a measurable improvement beyond the placebo effect.

SSRIs as the first line

Selective serotonin reuptake inhibitors (sertraline, escitalopram, citalopram, fluoxetine, paroxetine) are first-line medications due to their favorable safety profile. The therapeutic effect appears after 2-6 weeks, and full remission often requires 8-12 weeks. Side effects include transient nausea, sexual dysfunction, and insomnia.

SNRIs and other classes

Venlafaxine, duloxetine, and desvenlafaxine (SNRIs) are options when there is no response to SSRIs or in the presence of co-occurring pain syndromes. Bupropion acts on the dopaminergic-noradrenergic system, mirtazapine on 5-HT2 and histamine receptors, and agomelatine on melatonin receptors. TCAs (amitriptyline, clomipramine) are a reserve due to cardiotoxicity. MAOIs are rarely used and require a special diet.

Psychotherapy as a parallel pillar

Cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and behavioral activation therapy have documented efficacy comparable to pharmacotherapy in mild and moderate depression (WHO mhGAP, 2016). In severe depression, psychotherapy works better as an adjunct to pharmacotherapy. Newer approaches (ACT, mindfulness, MBCT) support relapse prevention.

Ketamine and esketamine in treatment-resistant depression

Esketamine (Spravato) was registered in 2019 by the EMA as a treatment for treatment-resistant depression, with a rapid antidepressant effect visible within 24 hours. It acts through the NMDA receptor and the mTOR-BDNF pathway. It is administered intranasally in specialized centers. The cost and availability in Poland are limited. ECT (electroconvulsive therapy) remains the most effective method in severe depression with psychotic symptoms.

Citation capsule: All 21 studied antidepressants are significantly more effective than placebo in treating depression, with NNT of 5-11, and combining pharmacotherapy and psychotherapy yields the best clinical results, constituting the first line that no supplement can replace (Cipriani et al., The Lancet, 2018).

How does CBD interact with antidepressants through CYP2C19 and CYP3A4?

CBD is a strong inhibitor of liver cytochromes CYP2C19, CYP3A4, CYP2D6, and CYP2C9, meaning it can significantly alter the concentration of other medications. A systematic review by Brown and Winterstein in 2019 identified over 139 drugs with potentially clinically significant interactions with CBD, including many antidepressants (Brown and Winterstein, Journal of Clinical Medicine, 2019). This is a key warning for anyone combining CBD supplementation with psychiatric medications.

SSRIs and CYP2C19

Citalopram, escitalopram, and sertraline are metabolized by CYP2C19. By inhibiting this enzyme, CBD may increase their concentration, which raises the risk of serotonin syndrome, QT interval prolongation, and cardiac arrhythmias. The FDA has issued a warning about a maximum daily dose of citalopram of 40 mg, and with a concurrent CYP2C19 inhibitor, even lower. CBD may necessitate a reduction in the dose of SSRIs.

SNRIs, TCAs, and CYP3A4/CYP2D6

Venlafaxine is metabolized by CYP2D6, and to a lesser extent by CYP3A4. TCAs (amitriptyline, clomipramine) are substrates of CYP2D6 and CYP1A2. Inhibition of these pathways by CBD may lead to accumulation of metabolites, sedation, orthostatic hypotension, and in the case of TCAs, cardiotoxicity. This class of drugs requires special caution.

MAOIs and absolute contraindication

Monoamine oxidase inhibitors (moclobemide, tranylcypromine, phenelzine) are a class of antidepressants with a high risk of food and drug interactions. Combining them with CBD is considered inadvisable due to the potential for hypertensive crisis and serotonin syndrome. Patients on MAOIs should not use CBD without psychiatric consultation.

Lithium, antipsychotics, and mood stabilizers

Valproate and CBD together increase the risk of hepatotoxicity, as documented in studies on Epidiolex. Clobazam requires a dose reduction of 25-50% when adding CBD due to increased levels of the active metabolite N-desmethylclobazam. Patients with bipolar disorder stabilized with lithium should consult on CBD supplementation, as mood effects alone may disrupt clinical observation.

Citation capsule: CBD is an inhibitor of CYP2C19, CYP3A4, CYP2D6, and CYP2C9, affecting the metabolism of over 139 drugs, including SSRIs, SNRIs, and TCAs, and combining with MAOIs is considered inadvisable due to the risk of serotonin syndrome and hypertensive crisis (Brown and Winterstein, Journal of Clinical Medicine, 2019).

/konopie-i-antydepresanty-czy-mozna-laczyc-leki-przeciwdepresyjne-z-cbd-i-marihuana/

How to safely and legally use CBD as support, never as a substitute?

CBD in Poland is legal as a dietary supplement and cosmetic provided that the THC content does not exceed 0.3% ("Regulations on cannabis", Ministry of Health, 2024). It is not registered as a drug for depression and cannot be promoted as an alternative to psychiatry. Any supplementation during psychiatric treatment requires consultation with the treating physician.

Low-dose protocol

Supplementation is usually started with low doses in a broad spectrum formula, such as SOOL CBD 5% oil (500 mg CBD in 10 ml). A practical protocol is 2-3 drops sublingually 1-2 times a day for the first 7-14 days, observing tolerance and well-being. It is advisable to keep a journal noting mood, sleep, anxiety, appetite, and any side effects.

Increasing the dose and 10% formula

After the adaptation period, if tolerance develops, it is possible to switch to SOOL CBD oil 10%, with typical doses of 25-50 mg of CBD daily in two portions. Doses of 300 mg and higher used in clinical studies require consultation, as at such amounts the risk of drug interactions increases and transient elevations in liver enzymes are observed.

CBG as a supplement for apathy

In consultations with clients at u Bucha, we observe that some individuals with depression characterized by anergia and apathy respond better to the combination of CBD with CBG than to CBD alone. Cannova CBG oil 15% (1500 mg in 10 ml) supports alpha-2-adrenergic receptors and TRPA1. However, it is worth noting that there is currently no solid clinical data on CBG supplementation for depression, only preclinical reports.

CBD hemp flower in vaporization

In states of acute stress and insomnia, which often accompany depression, some patients (with their doctor's consent) resort to vaporizing CBD hemp flower, such as Mars Dry CBD 9%. Vaporization provides a rapid onset of action (5-15 minutes) and higher bioavailability than oral oils. However, it is not a first-line form for depression, as the acute effect does not replace systematic treatment.

When absolutely not to use CBD alone

CBD is not suitable as monotherapy for individuals with suicidal thoughts, severe depression, bipolar disorder, psychosis, severe liver failure, during pregnancy and breastfeeding, or for those taking MAOIs, warfarin, clobazam, valproate, or immunosuppressants after transplants. In these situations, specialized treatment is a priority.

Citation capsule: CBD in Poland is a legal supplement with THC content below 0.3%, but it is not a registered drug for depression, and a safe starting protocol is 10-25 mg daily in broad spectrum oil, with mandatory psychiatric consultation for those treated with antidepressants (Ministry of Health, 2024).

What warning signs require immediate help, not supplementation?

Untreated depression is a potentially fatal illness. The lifetime risk of suicide in individuals with severe depression is about 4-6%, and in the population with a depressive episode hospitalized it reaches 8.6% (Bachmann, International Journal of Environmental Research and Public Health, 2018). Therefore, recognizing warning signs and responding quickly is crucial, far more important than choosing a supplement.

Suicidal thoughts and plans

The emergence of thoughts of death, "disinterest in life", suicidal plans, talking about being a burden to others, giving away valuable items, farewell messages are signals of acute life-threatening danger. In such a situation, one does not choose an oil, but calls 112 or 116 123, goes to the emergency room, or contacts a psychiatrist urgently. This is an absolute priority.

Psychotic symptoms

Delusions (feelings of guilt, innocent death, unisolated somatic illness), hallucinations, loss of contact with reality, deep motor retardation, or depressive stupor require psychiatric hospitalization. CBD has no place in this situation.

Perinatal depression

Depression during pregnancy and postpartum occurs in about 10-15% of women and increases the risk of complications for both mother and child. CBD supplementation during pregnancy and breastfeeding is not recommended due to unclear safety data for the fetus. Treatment is conducted by a perinatal psychiatrist, selecting medications with a well-researched profile.

Sudden deterioration due to withdrawal

Discontinuing antidepressants on one's own after starting CBD is one of the more common causes of relapse and suicidal crises. Withdrawal syndrome after SSRIs may include dizziness, "brain zaps", nausea, insomnia, and worsening depression. Discontinuation of medications should always be done gradually, under the supervision of a psychiatrist.

Hotlines and trust lines in Poland

In Poland, there are 24-hour help lines available: 112 (general emergency), 116 123 (Trust Line for Adults in Emotional Crisis), 116 111 (Trust Line for Children and Adolescents), 800 70 2222 (Support Center for People in Mental Crisis). They provide support anonymously and free of charge.

Citation capsule: The risk of suicide in severe depression reaches 4-6% over a lifetime, and among hospitalized individuals, it is 8.6%, so suicidal thoughts, psychotic symptoms, or deterioration after discontinuation of medications require immediate contact with a psychiatrist, 112, or 116 123, not supplementation (Bachmann, IJERPH, 2018).

/cbd-w-schizofrenii-badania-nad-przeciwpsychotycznym-dzialaniem-konopi/

How do lifestyle, sleep, and physical activity support the treatment of depression?

Lifestyle interventions have documented efficacy in treating depression, comparable to pharmacotherapy in mild cases and significantly improving outcomes in moderate and severe cases. Schuch's meta-analysis from 2016 showed that physical activity reduces symptoms of depression with a Cohen's d effect size of 1.11 with moderate aerobic training (Schuch et al., Journal of Psychiatric Research, 2016). This is one of the most consistent signals in psychiatry.

Physical activity and BDNF

Aerobic exercise for 150-300 minutes per week increases BDNF levels, stimulates neurogenesis in the hippocampus, and normalizes the HPA axis. The effects are visible after just 4-6 weeks of regular training. In mild depression, physical activity may be a first-line option, while in moderate and severe cases, it serves as a strong adjunct to pharmacotherapy. Resistance training also yields antidepressant effects.

Sleep and sleep hygiene

Sleep disorders are both a symptom and a risk factor for depression. Sleep fragmentation increases the reactivity of the amygdala and decreases the activation of the prefrontal cortex. Sleep hygiene includes consistent sleep hours, limiting screens before bed, reducing caffeine after 2 PM, and morning light exposure. CBT-I (cognitive-behavioral therapy for insomnia) has efficacy comparable to sleeping pills, without the risk of addiction.

Mediterranean diet and microbiome

A diet rich in vegetables, fruits, fish, nuts, and olive oil is associated with a lower risk of depression in population studies. The inflammatory hypothesis of depression explains this through the impact of omega-3 fatty acids and polyphenols on neuroinflammation. Studies on the gut-brain axis show that probiotics (Lactobacillus, Bifidobacterium strains) may have a modest effect on mood but do not replace standard therapy.

Stress reduction techniques, mindfulness, yoga

MBSR (Mindfulness-Based Stress Reduction) and MBCT (Mindfulness-Based Cognitive Therapy) programs have evidence of efficacy in preventing relapse in individuals with at least three episodes. Mindfulness-based practices, yoga, and meditation modulate the HPA axis, lower cortisol, and increase parasympathetic activity.

Light exposure and circadian rhythm

Light therapy of 10,000 lux in the morning for 20-30 minutes is standard in seasonal depression (SAD) but also supports other forms of depression. Stabilizing the circadian rhythm, waking up early, and exposure to sunlight support serotonin and melatonin production at the right times.

Citation capsule: Aerobic physical activity has an antidepressant effect of Cohen's d = 1.11, comparable to medications in mild depression, and sleep hygiene, Mediterranean diet, mindfulness, and light therapy are documented pillars supporting standard treatment (Schuch et al., Journal of Psychiatric Research, 2016).

Frequently asked questions about depression and cannabis (FAQ)

Can CBD cure depression?

No. CBD is not a medication for depression and has no registration for this indication. Clinical evidence is limited to observational studies and single pilot studies, and randomized controlled trials are still ongoing (ClinicalTrials.gov, 2025). Depression is treated by a psychiatrist using pharmacotherapy and psychotherapy. CBD may be an optional supplement after consultation, but never a substitute. Self-treatment of depression with CBD oil is dangerous and increases the risk of relapse and crisis.

How long after taking CBD will my mood improve?

In observational studies, the acute effect on mood appears 30-120 minutes after a sublingual dose, but it is more of a reduction in tension than an antidepressant effect. Like SSRIs, systematic improvement, if it occurs at all, requires 4-8 weeks of regular supplementation. The Stith study showed an average reduction in depression scores of 3.76 after a single dose, but without measuring long-term remission (Stith et al., Frontiers in Psychiatry, 2020).

Can I take CBD with sertraline or escitalopram?

Only after psychiatric consultation. CBD inhibits CYP2C19, which increases the concentration of sertraline, escitalopram, citalopram, and omeprazole by up to 40-60%. This may enhance the effects of SSRIs, raise the risk of serotonin syndrome, and prolong the QT interval. Some psychiatrists accept low doses of CBD (10-25 mg) in patients on SSRIs, monitoring symptoms. Never discontinue SSRIs on your own (Brown and Winterstein, Journal of Clinical Medicine, 2019).

Does marijuana help with depression or worsen it?

On a large population scale, regular use of THC-rich cannabis increases the risk of depression by 37% and suicidal thoughts by 46% in young adults (Gorfinkel et al., JAMA Network Open, 2024). Low doses of THC may temporarily improve mood, but long-term they predispose to depression, especially in individuals with a family burden, trauma, or previous anxiety symptoms. Recreational marijuana is not a treatment for depression.

Is CBD safe during pregnancy for postpartum depression?

It is not recommended. Safety data on CBD during pregnancy are incomplete, and its potential effects on the development of the fetal endocannabinoid system remain unknown. The FDA warns against using CBD during pregnancy and breastfeeding. Perinatal depression is treated by a psychiatrist, selecting medications with a well-documented safety profile (sertraline, escitalopram), and psychotherapy is the first line in mild forms.

Where to seek help in Poland during a depressive crisis?

In the case of an acute crisis, call 112 or 116 123 (Trust Line for Adults), 116 111 (children and adolescents). The Support Center for People in Mental Crisis 800 70 2222 operates 24/7. For a scheduled psychiatric consultation, the NFZ waiting list averages 3-6 months, while a private online visit costs 200-400 PLN. A list of trust lines is maintained by Forum Against Depression.

Summary: What we know, what we don't know, and how to sensibly use CBD in depression

Data from recent years, especially 2019-2025, show consistent preclinical signals that CBD may act antidepressantly through 5-HT1A, the BDNF-mTOR pathway, hippocampal neurogenesis, and regulation of the HPA axis. These mechanisms are the same that account for the action of classical antidepressants and rapid antidepressants like ketamine. In theory, CBD thus has rational grounds to be the subject of further clinical research in depression.

At the same time, evidence in humans remains limited to observational studies and open pilot studies, without large RCTs. This means that claims about the antidepressant efficacy of CBD in humans are today a hypothesis, not a fact. In Polish conditions, where depression affects about 4-5% of adults, and the waiting list for a psychiatrist in the NFZ lasts quarters, the temptation for self-treatment with oil is understandable but dangerous. Replacing psychiatry and psychotherapy with a supplement increases the risk of relapse, suicidal crisis, and loss of productive years.

The sensible order of actions remains the same: psychiatric consultation, risk assessment, implementation of first-line medication (SSRI or SNRI), parallel psychotherapy (CBT, IPT, or behavioral activation), lifestyle interventions (physical activity, sleep, diet, light therapy), and only then possible supplementation with CBD, after discussing it with the treating physician, especially in the context of CYP interactions. If you are considering broad spectrum support, it is worth starting with a low concentration like SOOL CBD 5% oil, with a mood journal and psychiatric control every 4-8 weeks.

Depression is an illness, not just temporary fatigue, and do not replace treatment with supplementation. In a mental crisis in Poland, call immediately 112 or 116 123 (Trust Line for Adults in Emotional Crisis). This is the most important number you should know, more important than any cannabis product.

/kategoria/oleje-cbd/

About the author

Michał Waluk is a cannabis education specialist collaborating with u Bucha. The articles are based on peer-reviewed publications from PubMed, Cochrane, and ClinicalTrials.gov, emphasizing the quality of evidence and the clinical context of Polish patients. The content is educational and does not replace medical advice.

Last updated: April 24, 2026.